OptimizeRx Corporation
OPRX
$15.27
-$0.11-0.72%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 26.07M | 29.20M | 21.93M | 32.32M | 21.31M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 26.07M | 29.20M | 21.93M | 32.32M | 21.31M |
| Cost of Revenue | 8.55M | 10.56M | 8.58M | 10.29M | 7.86M |
| Gross Profit | 17.52M | 18.64M | 13.34M | 22.02M | 13.45M |
| SG&A Expenses | 14.39M | 14.37M | 14.36M | 17.30M | 13.43M |
| Depreciation & Amortization | 1.08M | 1.07M | 1.09M | 1.09M | 1.10M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 24.02M | 26.01M | 24.04M | 28.68M | 22.38M |
| Operating Income | 2.05M | 3.19M | -2.11M | 3.63M | -1.07M |
| Income Before Tax | 1.05M | 1.71M | -3.28M | 2.21M | -9.94M |
| Income Tax Expenses | 270.00K | 181.00K | -1.09M | 2.29M | -817.00K |
| Earnings from Continuing Operations | 779.00K | 1.53M | -2.20M | -78.00K | -9.12M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 779.00K | 1.53M | -2.20M | -78.00K | -9.12M |
| EBIT | 2.05M | 3.19M | -2.11M | 3.63M | -1.07M |
| EBITDA | 2.99M | 4.13M | -1.17M | 5.14M | -132.00K |
| EPS Basic | 0.04 | 0.08 | -0.12 | 0.00 | -0.50 |
| Normalized Basic EPS | 0.04 | 0.06 | -0.11 | 0.07 | -0.08 |
| EPS Diluted | 0.04 | 0.08 | -0.12 | 0.00 | -0.50 |
| Normalized Diluted EPS | 0.03 | 0.06 | -0.11 | 0.07 | -0.08 |
| Average Basic Shares Outstanding | 18.58M | 18.51M | 18.47M | 18.42M | 18.32M |
| Average Diluted Shares Outstanding | 19.46M | 19.02M | 18.47M | 18.42M | 18.32M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |